Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis
J Chun, HP Hartung - Clinical neuropharmacology, 2010 - journals.lww.com
Fingolimod (FTY720) is a first-in-class orally bioavailable compound that has shown efficacy
in advanced clinical trials for the treatment of multiple sclerosis (MS). In vivo, fingolimod is …
in advanced clinical trials for the treatment of multiple sclerosis (MS). In vivo, fingolimod is …
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease
A Di Pardo, E Amico, M Favellato… - Human molecular …, 2014 - academic.oup.com
Huntington disease (HD) is a genetic neurodegenerative disorder for which there is currently
no cure and no way to stop or even slow the brain changes it causes. In the present study …
no cure and no way to stop or even slow the brain changes it causes. In the present study …
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
S Vasiliou - Drugs of Today (Barcelona, Spain: 1998), 2010 - europepmc.org
The sphingosine-1-phosphate receptor modulator fingolimod (FTY-720), which acts by
preventing lymphocyte egress from lymph nodes thus reducing lymphocyte infiltration into …
preventing lymphocyte egress from lymph nodes thus reducing lymphocyte infiltration into …
The impact of translational research on the development of therapeutic agents for multiple sclerosis
SL Cohan, EB Lucassen, KE Smoot… - Neurotherapeutics in the …, 2021 - Elsevier
Multiple sclerosis (MS) is a severe, progressive, and disabling disease, for which there were
no significant disease-modifying therapies until 25 years ago. The intervening years have …
no significant disease-modifying therapies until 25 years ago. The intervening years have …